__

Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.

Cannabis Science President and CEO Dr. Robert Melamede, PhD., commented, “Obviously, this study gives further support to our plans to work within the multi-billion dollar market of chronic neuropathic pain. As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?”

McGill’s study is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes. Participants were divided into four groups and randomly assigned marijuana containing four levels of tetrahydrocannabinol (THC), the active ingredient: at 9.4 per cent, 6.0 per cent, 2.5 per cent, and zero THC. The study was led by anesthesiologist Mark Ware, director of clinical research at Montreal’s Alan Edwards Pain Management Unit at the McGill University Health Centre. It was published in the Canadian Medical Association Journal.

Richard Cowan, Cannabis Science CFO, added, “This study demonstrates the importance of our licensing agreement with the RockBrook dispensary of Denver which we announced on August 18th, which gives us the immediate ability to test our formulations with humans to help determine exactly what doses and strains work best for patients as we prepare to enter clinical trials.”

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. Cannabis Science works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, Cannabis Science is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

http://www.cannabisscience.com

__

WindPower Innovations, Inc. (PINK SHEETS:WPNV), a wind power infrastructure and smart grid solutions company, reported yesterday the availability of a recent interview with Chief Technical Officer Ian K. Griffiths conducted by Virmmac.com, a virtual IR, marketing, media, and administration center focused on providing companies ongoing support, and Stocktalk101.com, designed to educate traders and investors alike in OTC and Pink sheet companies, will air the interview via a pod cast, on Tuesday, September 7th, 2010 at 09:00 am EDT. The interview will be available on Virmmac’s and Stocktalk101’s (www.stocktalk101.com) homepage. Mr. Griffiths will discuss in detail the unique nature of WindPower Innovations, Inc. and how it sees its role in the evolution of wind energy.

Furthermore, WindPower Innovations also reports talks with Energy Plus, an Alternative Energy Company, regarding distribution of WindPower Innovation’s Permanent Magnet Generator and Grid-Tie Technology throughout Mexico and Central America. Energy Plus distributes alternative energy solutions throughout Mexico and Latin America, and the invitation to expand its palette of offerings, helping to address the requirements of its long standing relationships, represents a strategic marketing opportunity for WindPower Innovations and Energy Plus.

“Many potential markets for wind energy are un-tapped because the technology most widely available requires constant wind speeds at only one to two optimum peaks (+/-5%),” says Ian Griffiths, Chief Technical Officer of WindPower Innovations. “Since it’s a smart technology that can sense variable load demands and adjust power output accordingly, our Permanent Magnet and custom Grid-Tie solutions are ideal for regions that have inconsistent wind supply or power grid challenges, meeting the varying power needs from country to country, small villages, extreme climates and/or areas with developing infrastructure. Constant power can be generated consistently over a very wide band of operation (from 20% TO 125% of rated power).”

WindPower Innovations, Inc., is a wind power infrastructure and smart grid solutions company that is continually working on new innovations for wind turbines, wind energy generation and transmission, in addition to the comprehensive maintenance, repair and re-manufacture of exiting equipment.

http://www.windpowerinnovationsinc.com

__

3M Co. (NYSE: MMM)

3M to Acquire Arizant Inc.

3M announced today it has entered into a definitive agreement to acquire Arizant Inc. for a purchase price of $810 million in cash. Based in Eden Prairie, Minn., Arizant is a leading manufacturer of patient warming solutions designed to prevent hypothermia in surgical settings.

“Patient warming is a highly strategic adjacency for our business and integral to infection prevention,” said Debra Rectenwald, president and general manager, 3M Infection Prevention Division. “In addition to Arizant’s market-leading products, its rich intellectual property portfolio and solid technology platforms expand 3M’s infection prevention offerings and will help to drive growth internationally, as well as provide a platform of innovative wound care technologies.”

Arizant created the category of forced-air patient warming with the introduction of Bair Hugger® therapy in 1987. The global opportunity for patient warming is approximately $1 billion, with the forced-air warming category expected to grow at about 10 percent per year.

Today, Arizant products help maintain normal body temperature, known as normothermia, in more than 20 million surgical patients annually as part of an effort to help prevent surgical site infections and other serious complications associated with surgical hypothermia. Numerous clinical studies demonstrate the effectiveness of these products to reduce the incident rates of hypothermia. Arizant’s normothermia technology also has applications in wound healing and will augment 3M’s technology base in this market as well.

Fueled by the success of Bair Hugger therapy, Arizant has continuously displayed its dedication to innovation through other ground-breaking temperature management products, including the Bair Paws® patient adjustable warming system, the world’s first warming gown designed for perioperative use, and the Ranger® blood and fluid warming systems, a market leader in dry-heat blood and fluid warming.

3M’s infection prevention business helps hospitals reduce healthcare-associated infections. Its wide variety of products and systems for controlling the risk of infection includes applications for sterilization and monitoring, hand hygiene, perioperative preps, and surgical drapes.

A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M’s core strength is applying its more than 40 distinct technology platforms – often in combination – to a wide array of customer needs. With $23 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 65 countries.

www.3M.com

__

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars from a third party (VNC Associates LLC) for one (1) day of advertising for CANNABIS SCIENCE INC (OTC BB: CBIS.OB).

____________________

Sign Up for our FREE Daily Stock Newsletter

____________________

<

 

 

Tags:

3M |  Arizant |  Cannabis Science |  CBIS |  MMM |  NYSE:MMM |  otc:cbis |  PINK:WPNV |  WindPower Innovations